行情

SYBX

SYBX

Synlogic
NASDAQ

实时行情|Nasdaq Last Sale

2.810
+0.070
+2.55%
盘后: 2.810 0 0.00% 16:00 12/11 EST
开盘
2.950
昨收
2.740
最高
3.000
最低
2.620
成交量
86.39万
成交额
--
52周最高
11.43
52周最低
1.910
市值
9,073.72万
市盈率(TTM)
-1.5396
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SYBX 新闻

  • SBGL, OLLI among premarket gainers
  • Seeking Alpha - Article.16小时前
  • Synlogic up 6% premarket on advancement of PKU candidate
  • Seeking Alpha - Article.17小时前
  • Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
  • Business Wire.20小时前
  • Biotech accelerator teams with investment firm for $210M fund raise
  • American City Business Journals.1天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

SYBX 简况

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
展开

Webull提供Synlogic Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。